Brief Research ReportPublished 9 October 2026Comparative genomic analysis of established and emerging anti-tubercular drug targets reveals evolutionary conservation and antimicrobial resistance patterns in Mycobacterium tuberculosis isolates from IndonesiaNi Made Puspawati · Iryanti Eka Suprihatin · Akshay Suthar · Ashaka Vansia · Rajesh PatelFrontiers in Tropical Diseasesdoi 10.3389/fitd.2026.1953716
Original ResearchPublished 2 October 2026High-throughput screening to identify inhibitors of the MTB CARD•RNA polymerase protein-protein interactionGlory M. Velazquez · Jonathan Z. Sexton · Scott G. Franzblau · Gauri S. Shetye · Akil Hossain · George A. GarciaFrontiers in Tuberculosisdoi 10.3389/ftubr.2026.1937953
ReviewPublished 3 September 2026Multi-homosubunit dsRNA/dsDNA virus genome packaging nanomotors with sequential revolving mechanisms for potent drug developmentMargaret Bohmer · Justin Gnarra · Daniel W. Binzel · Tao Weitao · Peixuan GuoFrontiers in RNA Researchdoi 10.3389/frnar.2026.1870177
Original ResearchPublished 13 January 2026Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named “Regimen C” for pre-XDR tuberculosis in NigerSoumana Boubacar Soumana · Abdourahamane Yacouba · Cheikh Aboubacar Abdoul Lawi · Ibrahim Oumar · Bassirou Souleymane · Alphazazi Soumana · Tapha Ounoussa · Mahamadou Doutchi · Mamane Daou · Souleymane Brah · Eric Adehossi · Saidou MamadouFrontiers in Tuberculosisdoi 10.3389/ftubr.2025.1718997
TuberculosisPublished 25 September 2025Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy developmentNaomi M. Fuller · Nicholas G. Davies · Timothy D. McHugh · Gwenan M. KnightFrontiers in Tuberculosisdoi 10.3389/ftubr.2025.1667354
